Polyneuron develops a new drug class for the treatment of autoimmune diseases affecting the nervous system. Their Antibody-Catch™ platform technology enables the rational design of immunomodulatory compounds that selectively eliminate disease-causing autoantibodies. The platform carries the potential to realize breakthrough therapies for specific autoimmune conditions.